454 related articles for article (PubMed ID: 32659332)
21. Efficacy, Predictive Factors, and Prediction Nomograms for
Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
[TBL] [Abstract][Full Text] [Related]
22. Salvage Reirradiation for Locally Recurrent Prostate Cancer: Results From a Prospective Study With 7.2 Years of Follow-Up.
Ekanger C; Helle SI; Reisæter L; Hysing LB; Kvåle R; Honoré A; Gravdal K; Pilskog S; Dahl O
J Clin Oncol; 2024 Jun; 42(16):1934-1942. PubMed ID: 38652872
[TBL] [Abstract][Full Text] [Related]
23. Stereotactic Body Radiation Therapy Salvage for Lymph Node Recurrent Prostate Cancer in the Era of PSMA PET Imaging.
Hayek OE; Rais-Bahrami S; McDonald A; Galgano SJ
Curr Urol Rep; 2023 Oct; 24(10):471-476. PubMed ID: 37395949
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic Body Radiation Therapy to the Prostate Bed: Results of a Phase 1 Dose-Escalation Trial.
Sampath S; Frankel P; Vecchio BD; Ruel N; Yuh B; Liu A; Tsai T; Wong J
Int J Radiat Oncol Biol Phys; 2020 Mar; 106(3):537-545. PubMed ID: 31733323
[TBL] [Abstract][Full Text] [Related]
25. Salvage reirradiation for local prostate cancer recurrence after radiation therapy. For who? When? How?
Baty M; Créhange G; Pasquier D; Palard X; Deleuze A; Gnep K; Key S; Beuzit L; Castelli J; de Crevoisier R
Cancer Radiother; 2019 Oct; 23(6-7):541-558. PubMed ID: 31421999
[TBL] [Abstract][Full Text] [Related]
26. Focal MRI-Guided Salvage High-Dose-Rate Brachytherapy in Patients With Radiorecurrent Prostate Cancer.
Maenhout M; Peters M; van Vulpen M; Moerland MA; Meijer RP; van den Bosch MAAJ; Nguyen PL; Frank SJ; van der Voort van Zyp JRN
Technol Cancer Res Treat; 2017 Dec; 16(6):1194-1201. PubMed ID: 29333958
[TBL] [Abstract][Full Text] [Related]
27. Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes.
Kotecha R; Djemil T; Tendulkar RD; Reddy CA; Thousand RA; Vassil A; Stovsky M; Berglund RK; Klein EA; Stephans KL
Int J Radiat Oncol Biol Phys; 2016 Jul; 95(3):960-964. PubMed ID: 27302511
[TBL] [Abstract][Full Text] [Related]
28. A Prospective Study of 18F-DCFPyL PSMA PET/CT Restaging in Recurrent Prostate Cancer following Primary External Beam Radiotherapy or Brachytherapy.
Liu W; Zukotynski K; Emmett L; Chung HT; Chung P; Wolfson R; Rachinsky I; Kapoor A; Metser U; Loblaw A; Morton G; Sexton T; Lock M; Helou J; Berlin A; Boylan C; Archer S; Pond GR; Bauman G
Int J Radiat Oncol Biol Phys; 2020 Mar; 106(3):546-555. PubMed ID: 31730876
[TBL] [Abstract][Full Text] [Related]
29.
Marzec J; Becker J; Paulsen F; Wegener D; Olthof SC; Pfannenberg C; Schwenck J; Bedke J; Stenzl A; Nikolaou K; la Fougère C; Zips D; Müller AC
Acta Oncol; 2020 Feb; 59(2):149-156. PubMed ID: 31559880
[No Abstract] [Full Text] [Related]
30. Stereotactic Body Radiation Therapy Boost for Intermediate-Risk Prostate Cancer: A Phase 1 Dose-Escalation Study.
Alayed Y; Loblaw A; Chu W; Al-Hanaqta M; Chiang A; Jain S; Chung H; Vesprini D; Morton G; Ravi A; Davidson M; Deabreu A; Mamedov A; Zhang L; Erler D; Cheung P
Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1066-1073. PubMed ID: 31002941
[TBL] [Abstract][Full Text] [Related]
31. Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer : Long-term results and factors predictive for outcome and toxicity.
Franzese C; Badalamenti M; Di Brina L; D'Agostino G; Franceschini D; Comito T; Clerici E; Navarria P; Reggiori G; Mancosu P; Tomatis S; Scorsetti M
Strahlenther Onkol; 2020 Jul; 196(7):608-616. PubMed ID: 32303782
[TBL] [Abstract][Full Text] [Related]
32. Five-Year Outcomes of a Phase 1 Dose-Escalation Study Using Stereotactic Body Radiosurgery for Patients With Low-Risk and Intermediate-Risk Prostate Cancer.
Zelefsky MJ; Kollmeier M; McBride S; Varghese M; Mychalczak B; Gewanter R; Garg MK; Happersett L; Goldman DA; Pei I; Lin M; Zhang Z; Cox BW
Int J Radiat Oncol Biol Phys; 2019 May; 104(1):42-49. PubMed ID: 30611838
[TBL] [Abstract][Full Text] [Related]
33. A Phase 1 Trial of Focal Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer.
Patel KR; Rydzewski NR; Schott E; Cooley-Zgela T; Ning H; Cheng J; Salerno K; Huang EP; Pinto PA; Lindenberg L; Mena E; Choyke P; Turkbey B; Citrin DE
Pract Radiat Oncol; 2023; 13(6):540-550. PubMed ID: 37442430
[TBL] [Abstract][Full Text] [Related]
34. ¹⁸F-choline positron emission tomography/computed tomography-driven high-dose salvage radiation therapy in patients with biochemical progression after radical prostatectomy: feasibility study in 60 patients.
D'Angelillo RM; Sciuto R; Ramella S; Papalia R; Jereczek-Fossa BA; Trodella LE; Fiore M; Gallucci M; Maini CL; Trodella L
Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):296-302. PubMed ID: 25084612
[TBL] [Abstract][Full Text] [Related]
35.
Bowden P; See AW; So K; Lawrentschuk N; Moon D; Murphy DG; Rao R; Crosthwaite A; King D; Haxhimolla H; Grummet J; Ruljancich P; Gyomber D; Landau A; Campbell N; Frydenberg M; Smyth LML; Nolan S; Gwini SM; McKenzie DP
World J Urol; 2021 Nov; 39(11):4117-4125. PubMed ID: 34076753
[TBL] [Abstract][Full Text] [Related]
36. Robotic image-guided stereotactic radiotherapy, for isolated recurrent primary, lymph node or metastatic prostate cancer.
Jereczek-Fossa BA; Beltramo G; Fariselli L; Fodor C; Santoro L; Vavassori A; Zerini D; Gherardi F; Ascione C; Bossi-Zanetti I; Mauro R; Bregantin A; Bianchi LC; De Cobelli O; Orecchia R
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):889-97. PubMed ID: 21277113
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of accelerated Linac-based SBRT in five consecutive fractions for localized prostate cancer.
Alongi F; Mazzola R; Fiorentino A; Corradini S; Aiello D; Figlia V; Gregucci F; Ballario R; Cavalleri S; Ruggieri R
Strahlenther Onkol; 2019 Feb; 195(2):113-120. PubMed ID: 30003292
[TBL] [Abstract][Full Text] [Related]
38. Patterns of relapse as determined by
Henkenberens C; Derlin T; Bengel FM; Ross TL; Wester HJ; Hueper K; Kuczyk MA; Christiansen H; von Klot CA
Strahlenther Onkol; 2018 Apr; 194(4):303-310. PubMed ID: 29134231
[TBL] [Abstract][Full Text] [Related]
39. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
[TBL] [Abstract][Full Text] [Related]
40. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes.
Chen CP; Weinberg V; Shinohara K; Roach M; Nash M; Gottschalk A; Chang AJ; Hsu IC
Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):324-9. PubMed ID: 23474112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]